Right—if they do pursue NSCLC for NKTR-214 + Opdivo, it certainly won't be for first-line PD-L1-positive. But I have serious doubts that they'll go to phase-3 at all in NSCLC.
For BMY, there's a cannibalization risk with respect to the Opdivo + Yervoy program in high-TMB NSCLC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.